Fulminant myocarditis with myositis after treatment with immune checkpoint inhibitors

被引：0
|
作者：
Vargas-Osorio, K. [1 ]
Prada Ramallal, G. [1 ]
Gonzalez-Ferrero, T. [2 ]
Cameselle-Teijeiro, J. M. [1 ,3 ,4 ]
机构：
[1] Clin Univ Hosp Santiago, Pathol Serv, La Coruna, Spain
[2] Univ Hosp Lucus Augusti, Serv Cardiol, Lugo, Spain
[3] Hlth Res Inst Santiago de Compostela IDIS, La Coruna, Spain
[4] Univ Santiago de Compostela, Dept Pathol, La Coruna, Spain
来源：
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | 2024年 / 135卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
12
引用
收藏
页码：26 / 27
页数：2
相关论文
共 50 条
  • [31] Immune checkpoint inhibitors (ICIs)-related ocular myositis
    Garibaldi, Matteo
    Calabro, Fabio
    Merlonghi, Gioia
    Pugliese, Silvia
    Ceccanti, Marco
    Cristiano, Lara
    Tartaglione, Tommaso
    Petrucci, Antonio
    NEUROMUSCULAR DISORDERS, 2020, 30 (05) : 420 - 423
  • [32] Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer
    Touat, Mehdi
    Maisonobe, Thierry
    Knauss, Samuel
    Salem, Omar Ben Hadj
    Hervier, Baptiste
    Aure, Karine
    Szwebel, Tali-Anne
    Kramkimel, Nora
    Lethrosne, Claire
    Bruch, Jean-Frederic
    Laly, Pauline
    Cadranel, Jacques
    Weiss, Nicolas
    Behin, Anthony
    Allenbach, Yves
    Benveniste, Olivier
    Lenglet, Timothee
    Psimaras, Dimitri
    Stenzel, Werner
    Leonard-Louis, Sarah
    NEUROLOGY, 2018, 91 (10) : E985 - E994
  • [33] Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab
    Yamaguchi, Shogo
    Morimoto, Ryota
    Okumura, Takahiro
    Yamashita, Yuta
    Haga, Tomoaki
    Kuwayama, Tasuku
    Yokoi, Tsuyoshi
    Hiraiwa, Hiroaki
    Kondo, Toru
    Sugiura, Yuki
    Watanabe, Naoki
    Kano, Naoaki
    Kohno, Kei
    Fukaya, Kenji
    Sawamura, Akinori
    Yokota, Kenji
    Ishii, Hideki
    Nakaguro, Masato
    Akiyama, Masashi
    Murohara, Toyoaki
    CANADIAN JOURNAL OF CARDIOLOGY, 2018, 34 (06) : 812.e1 - 812.e3
  • [34] Immune checkpoint inhibitors (ICIs)-related ocular myositis
    Garibaldi, M.
    Calabro, F.
    Merlonghi, G.
    Pugliese, S.
    Cristiano, L.
    Tartaglione, T.
    Petrucci, A.
    NEUROMUSCULAR DISORDERS, 2019, 29 : S78 - S78
  • [35] Pathogenesis of myocarditis following treatment with immune checkpoint inhibitors in a cynomolgus monkey model
    Ji, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [36] Increased myositis and possible myocarditis in melanoma patients treated with immune checkpoint inhibitors in the COVID-19 era
    Gradone, Allison L.
    Ma, Vincent T.
    Vasbinder, Alexi
    Fecher, Leslie A.
    Yentz, Sarah
    Hayek, Salim S.
    Lao, Christopher D.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (12)
  • [37] Visceral leishmaniasis after treatment with immune checkpoint inhibitors
    Drexler, Konstantin
    Utpatel, Kirsten
    Eholzer, Lisa Hannah
    Berneburg, Mark
    Haferkamp, Sebastian
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 (01): : 119 - 121
  • [38] Myocarditis Induced by Immune Checkpoint Inhibitors: An Exploratory Review
    Zavaleta-Monestel, Esteban
    Garcia-Montero, Jonathan
    Anchia-Alfaro, Adriana
    Rojas-Chinchilla, Carolina
    Quesada-Villasenor, Ricardo
    Arguedas-Chacon, Sebastian
    Barrantes-Lopez, Monserrat
    Molina-Sojo, Paula
    Zovi, Andrea
    Zuniga-Orlich, Carlos
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (08)
  • [39] Drug therapy for myocarditis induced by immune checkpoint inhibitors
    Wu, Yihao
    Xu, Yizhou
    Xu, Linhao
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [40] Encephalomyeloneuritis and arthritis after treatment with immune checkpoint inhibitors
    Nowosielski, Martha
    Di Pauli, Franziska
    Iglseder, Sarah
    Wagner, Michaela
    Hoellweger, Nicole
    Van Anh Nguyen
    Gruber, Johann
    Stockhammer, Guenther
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2020, 7 (04):
12345